🔗 Share this article

As the United States proceeds with sweeping adjustments to its vaccine guidelines, one figure appears in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about coronavirus shots throughout the pandemic and has focused upon alleged fatalities following Covid immunization in her recent position at the FDA.

Proposed Changes to Childhood Vaccine Program

Agency leaders were set to reveal sweeping revisions to the pediatric vaccination calendar in December, bringing the US with the Danish immunization schedule, sources say – a significant shift that would put the US out of step with many the international standard with little proof for improved outcomes. This reveal has been delayed until the new year.

In place of Vinay Prasad, Tracy Beth Høeg is set to speak at the meeting. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the division this year.

A New Direction at the Agency

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad solidify control at the agency – and it signals a increased emphasis upon rolling back previously authorized vaccines at the FDA.

The new acting director has repeatedly called for halting specific childhood immunization guidelines in the US to become more in line with Denmark's approach, a society with comprehensive healthcare and a citizenry about the size of the state of Wisconsin.

To date statements, she has persisted in emphasizing on immunizations – usually the responsibility of Prasad, director of the FDA’s CBER – instead of medication approval.

Doubts Over Background

Dr. Høeg has no apparent experience in medication creation, oversight or administrative roles, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the commissioner and CBER since spring.

“It seems she lacks to have the necessary background” for overseeing the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in running a sizeable institution. She is not an expert in drug approvals.”

Former directors of CBER would “understand regulatory frameworks and the research of drug development”, commented Dr. Janet Woodcock. “Objectively, she doesn’t have the sort of resume that prior appointees who ran CBER have had.”

This division has an enormous portfolio at the FDA, the former commissioner pointed out.

“Everybody just pays attention on the innovative therapies, but the generic program approves thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and more, and every single one need to be managed,” Woodcock said. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a major administrative aspect to the role, which supervises more than 5,000 personnel. “It is a enormous leadership role, if you perform it correctly,” Woodcock added.

Response and Contentious Policies

In response to concerns about Høeg’s fitness for the role and whether this selection indicates increased cooperation among FDA leaders on immunizations, a representative stated that the “questions rely on flawed premises”.

“Her experience is consistent with the duties of her role,” the spokesperson said, citing the months Dr. Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Dr. Høeg takes over the agency head's controversial fast-track approval initiative, a contentious one-day therapy clearance system that allegedly troubled her preceding directors. “By what process are these medications being picked for this expedited pathway? Who takes the decisions?” Dr. Howard asked. “There’s a lot of secrecy happening at the FDA right now.”

In general, he stated, “the agency seems to be moving towards laxer rules of pharmaceuticals, except for vaccines.”

Public Past Work on Vaccines

Concerning vaccines, Høeg has a more established, if concerning, track record, critics said. She authored a analysis using non-validated public submissions to estimate the frequency of heart inflammation following COVID-19 immunization. She advised the Florida top health official Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccines are riskier than they are.

Among her “wish list” for the incoming administration encompassed revising guidelines for novel immunizations and ending “non-essential” immunizations, she stated after the election on a online show. At the agency, Høeg has reportedly floated the idea of excluding young men from obtaining COVID-19 vaccines.

“She’s an all-around true believer who commences with her conclusions and tailors the evidence to accommodate the data in a very misleading, fraudulent fashion,” Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with other dissenters, {like|